Seagen, A Wholly Owned Subsidiary Of Pfizer

This early-stage study tests an experimental drug called SGN-MesoC2 in people with advanced solid tumors that have not responded to standard treatments. The drug is designed to attach to cancer cells and kill them. The study aims to find a safe dose and check for side effects in …

This study tests whether adding the drug tucatinib to standard therapy (trastuzumab and pertuzumab) can delay cancer growth in people with advanced HER2+ breast cancer that cannot be removed or has spread. About 654 participants will receive either tucatinib or a placebo pill, al…

This study is testing a drug called tucatinib combined with other cancer medicines (trastuzumab, chemotherapy, and pembrolizumab) in people with HER2-positive cancers of the digestive system. The main goals are to find safe doses and see what side effects occur. About 40 adults w…

This early-stage study tests a new drug, PF-08046049/SGN-BB228, for safety in people with advanced melanoma and other solid tumors that have spread or stopped responding to standard treatments. About 41 participants will receive the drug to find the right dose and check for side …

This study tests a two-drug combination (tucatinib and trastuzumab) in people with advanced solid tumors that have HER2 alterations. The goal is to see if the treatment can shrink or control tumors. About 217 participants with various cancers (like lung, uterine, or bile duct) wi…

This study tests whether adding tucatinib (a targeted pill) to standard T-DM1 therapy works better than T-DM1 alone for people with advanced HER2-positive breast cancer that has spread or can't be removed surgically. About 466 participants will receive either tucatinib or a place…

This study tests if adding the drug brentuximab vedotin to two standard lymphoma drugs (lenalidomide and rituximab) helps people with a type of blood cancer called diffuse large B-cell lymphoma that has returned or not responded to prior treatments. About 239 adults will be rando…

This study tests whether a combination of two drugs, disitamab vedotin and pembrolizumab, works better than standard chemotherapy for people with advanced bladder or urinary tract cancer that has spread. About 412 participants will be randomly assigned to receive either the new c…

This study tests a new experimental drug, sigvotatug vedotin, against a standard chemotherapy, docetaxel, in people with advanced non-small cell lung cancer that has spread or can't be removed. The goal is to see if the new drug helps people live longer and with fewer side effect…

This study tests a drug called tisotumab vedotin, alone or with other cancer medicines, in people with advanced colorectal, lung, pancreatic, or head and neck cancers that have stopped responding to standard treatments. About 350 participants receive different dosing schedules to…

This study tests an experimental drug called disitamab vedotin in people with advanced head and neck, lung, endometrial, or ovarian cancers that have a HER2 marker. The drug is designed to stick to cancer cells and kill them. About 120 adults will receive the drug every two weeks…